{
    "body": "GV1001 vaccine targets which enzyme?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24815142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19072345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24954781", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21377838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19388882", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23827187", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20822343", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22841437", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21586625", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24919654", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24439482", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24411674"
    ], 
    "ideal_answer": [
        "GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence. It has been developed as a vaccine against various cancers."
    ], 
    "exact_answer": [
        "human telomerase reverse transcriptase"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014612", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798"
    ], 
    "type": "factoid", 
    "id": "56c1f02cef6e39474100004c", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 136, 
            "text": "A reverse-transcriptase-subunit of telomerase (hTERT) derived peptide, GV1001, has been developed as a vaccine against various cancers. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24411674", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 97, 
            "text": "Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24919654", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 120, 
            "offsetInEndSection": 365, 
            "text": "A study was conducted to investigate safety and immunogenicity in non-resectable pancreatic carcinoma patients using a 16-amino acid telomerase peptide (GV1001) for vaccination in combination with GM-CSF and gemcitabine as first line treatment. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24919654", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1461, 
            "offsetInEndSection": 1596, 
            "text": "Telomerase vaccination (GV1001) in combination with chemotherapy appeared to be safe but the immune responses were weak and transient. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24919654", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 197, 
            "text": "Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24954781", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 216, 
            "text": "BACKGROUND: We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24954781", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 152, 
            "text": "Novel vaccine peptide GV1001 effectively blocks \u03b2-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24439482", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 107, 
            "text": "GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24439482", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 997, 
            "offsetInEndSection": 1379, 
            "text": "Together, these results suggest that GV1001 possesses neuroprotective effects against A\u03b2\u2082\u2085\u208b\u2083\u2085 oligomer in NSCs and that these effects are mediated through mimicking the extra-telomeric functions of human telomerase reverse transcriptase, including the induction of cellular proliferation, anti-apoptotic effects, mitochondrial stabilization, and anti-aging and anti-oxidant effects.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24439482", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 101, 
            "offsetInEndSection": 307, 
            "text": "Peptide GV1001 is a peptide vaccine representing a 16-amino acid human telomerase reverse transcriptase sequence, which has been reported to possess potential antineoplastic and anti-inflammatory activity. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24815142", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 990, 
            "offsetInEndSection": 1232, 
            "text": "Based on this review, the most promising current telomerase targeting therapeutics are the antisense oligonucleotide inhibitor GRN163L and immunotherapies that use dendritic cells (GRVAC1), hTERT peptide (GV1001) or cryptic peptides (Vx-001).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841437", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 135, 
            "text": "A reverse-transcriptase-subunit of telomerase (hTERT) derived peptide, GV1001, has been developed as a vaccine against various cancers.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23827187", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 680, 
            "offsetInEndSection": 784, 
            "text": "Of the increasing number of immunological agents, the GV1001 antitelomerase vaccine holds some interest.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19072345", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 135, 
            "text": "A reverse-transcriptase-subunit of telomerase (hTERT) derived peptide, GV1001, has been developed as a vaccine against various cancers.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24411674", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 293, 
            "offsetInEndSection": 498, 
            "text": "Peptide GV1001 is a peptide vaccine representing a 16-amino acid human telomerase reverse transcriptase sequence, which has been reported to possess potential antineoplastic and anti-inflammatory activity.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24815142", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 485, 
            "offsetInEndSection": 678, 
            "text": "It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822343", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 134, 
            "text": "GV1001 is a telomerase-specific, promiscuous class II peptide vaccine which is currently in an advanced stage of clinical development.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822343", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 204, 
            "text": "The study is a proof-of-principle trial evaluating toxicity, immune response, and clinical response in melanoma patients after combined therapy with temozolomide and the telomerase peptide vaccine GV1001.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21586625", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 131, 
            "text": "Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21377838", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 136, 
            "offsetInEndSection": 488, 
            "text": "This article reviews the biological rationale underpinning the design of ongoing studies with the vaccine as well as its immunogenicity and clinical activity. It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822343", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 295, 
            "offsetInEndSection": 491, 
            "text": "It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.  .", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822343", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 215, 
            "offsetInEndSection": 496, 
            "text": "Human telomerase reverse transcriptase (hTERT), the rate-limiting subunit of the telomerase complex, is therefore an attractive target for cancer vaccination. The present review provides an update on the development of GV1001, a peptide vaccine representing a 16-aa hTERT sequence.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19388882", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 295, 
            "offsetInEndSection": 488, 
            "text": "It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822343", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 582, 
            "offsetInEndSection": 686, 
            "text": "Of the increasing number of immunological agents, the GV1001 antitelomerase vaccine holds some interest.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19072345", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 108, 
            "text": "GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24439482", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 991, 
            "offsetInEndSection": 1233, 
            "text": "Based on this review, the most promising current telomerase targeting therapeutics are the antisense oligonucleotide inhibitor GRN163L and immunotherapies that use dendritic cells (GRVAC1), hTERT peptide (GV1001) or cryptic peptides (Vx-001).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841437", 
            "endSection": "abstract"
        }
    ]
}